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TO THE EDITOR
Many patients (37–88%) with psoriasis
believe that there is a causal relationship
between stressors and their skin disease
(Gupta et al., 1989; Nevitt and Hutch-
inson, 1996; Yosipovitch et al., 2000;
O’Leary et al., 2004; Zachariae et al.,
2004; Fortune et al., 1998, 2005), and
this relationship has received increasing
attention over the years (Pacan et al.,
2003; Reich et al., 2003; Gaston et al.,
1991). Although some earlier studies
have found that over 60% of the patients
with psoriasis retrospectively report to
have experienced stressful life events in
the month before the exacerbation of
their skin disease (Gupta et al., 1988;
Pacan et al., 2003; Reich et al., 2003),
evidence for a prospective relationship
between stressors and disease outcome
is, thus far, lacking. The aim of this study
is therefore to investigate the relationship
between the experience of daily stressors
and the change in disease outcome
(disease severity and itch) 4 weeks later
in patients with psoriasis. We hypothe-
sized that only at moments of relatively
high levels of daily stressors there would
be a relationship between stressors and
an increase in itch and disease severity 4
weeks later.
Participants for this study were re-
cruited from the Departments of Derma-
tology at the University Medical Centre
St Radboud and the Canisius Wilhelmina
Hospital, Nijmegen, the Netherlands.
This study was approved by relevant
ethics committees and conducted ac-
cording to the Helsinki principles. Writ-
ten inform consent was obtained from all
participants. For the purpose of this
study, the participants were followed
up for over 6 months with monthly
measures of disease severity (Psoriasis
Area and Severity Index (PASI); Freder-
iksson and Pettersson, 1978), itch impact
of skin diseases on daily life (ISDL;
Evers et al., 2008), and daily stressors
(everyday problem check list (EPCL);
Dekkers et al., 2001; Vingerhoets et al.,
1989). The study sample consisted of 62
patients with a mean age of 52.3 years
(SD 13.2 years, range 21.9–79.7) at the
start of the study. Of all the participants,
72.6% were male and 27.4% were
female. Furthermore, 4.8, 66.1, and
29.1% of them had a primary, second-
ary, and tertiary education level, respec-
tively. For each participant, the month in
which the participant reported the most
daily stressors (highest EPCL score), as
well as the month in which they reported
the least, (lowest EPCL score) was
determined. Prospective relationships
between daily stressors and changes in
disease outcome 4 weeks later were
subsequently examined by calculating
Pearson’s correlation coefficients be-
tween the EPCL daily stressor scores
and the change in disease severity (PASI)
and itch. For this purpose, residual gain
scores were used to measure the change
in PASI and itch. These scores take into
account the individual baseline levels
and the control for regression to the
mean effects (Kerlinger, 1975).
Mean levels of disease severity, itch,
and daily stressors in the month in which
patients experienced the highest and
lowest levels of daily stressors are pre-
sented in Table 1, showing significant
differences between the moments of
highest and lowest reported daily stres-
sors. When patients reported the highest
level of daily stressors, they also experi-
enced significantly more itch and a more
severe disease than when they reported
the lowest level of daily stressors. In
addition, Pearson’s correlation coeffi-
cients between daily stressors and
changes in disease severity (PASI) and
itch 4 weeks later are presented in
Table 2. Only at the moment that patients
reported the highest amount of daily
stressors there was a positive, significant
correlation between daily stressors andAbbreviations: PASI, psoriasis area and severity index
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the increase in disease severity (PASI) and
itch. No such relationships were found at
the moment patients reported the lowest
amount of daily stressors, nor any at other
monthly measurement moments (data
not shown). None of the demographic
variables (gender, age, and educational
level) was further related to the change in
disease severity (PASI) or itch at this
moment of highest or lowest stress (data
not shown).
Our results are in line with those of
other studies focusing on the relationship
between stressors and disease outcome.
For example, significant prospective re-
lationships between daily stressors and
an increase in disease severity have been
reported in patients with atopic dermatitis
(King and Wilson, 1991; Salewski and
Lissner, 2002). For other chronic inflam-
matory diseases, such as rheumatoid
arthritis, prospective relationships be-
tween daily stressors and disease severity
have also particularly been found at
moments when patients reported heigh-
tened levels of stressors (Affleck et al.,
1997; Zautra et al., 1997, 1998). These
findings support the idea that, in parti-
cular, the experience of a relatively high
level of daily stressors can influence the
course of chronic inflammatory diseases,
including psoriasis.
When interpreting the results of this
study, several limitations have to be kept
in mind. Although the patients who
completed this study did not differ from
non-completers, there could have been
a selection bias because more than half
of our study population consisted of
older males. Although gender differ-
ences have been reported, for example,
in the hypothalamic–pituitary–adreno-
cortical axis response to psychological
stressors, future studies should address
the influence of gender on the stress–
disease relationship (Kudielka and
Kirschbaum, 2005). Furthermore, to
control for medication effects, we in-
cluded only patients whose medication
regimen was stable in the 3 months
before the start of the study, which might
explain the rather low disease severity in
the study sample. Moreover, during this
study we had to exclude six patients
because their medication regimen was
changed, which suggests that the disease
severity also showed less variability than
usual. In addition, we cannot exclude
the fact that the study design with
repeated assessments might have influ-
enced patients’ attitudes and behavior,
such as compliance with applying topi-
cal medication.
To our knowledge, only preliminary
prospective results have been reported
earlier about the influence of daily
stressors on disease severity and itch in
patients with psoriasis. Although our
results should be replicated, our findings
indicate that the possible effect of daily
stressors on disease outcome should be
noticed within daily practice, particularly
when patients report that they are going
through a stressful period.
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TO THE EDITOR
Stem cells are multipotent cells capable
of self-replicating and differentiating
into several lineages of cells. In the
skin, stem cells reside in the hair follicle
bulge areas throughout the hair cycling,
growth (anagen), involution (catagen),
and rest (telogen) stages (Cotsarelis
et al., 1990; Paus and Cotsarelis,
1999; Cotsarelis, 2006). The stem cells
in the hair bulge can differentiate into
cells of hair follicles, sebaceous glands,
and interfollicular epidermis (Oshima
et al., 2001). The lack of hair follicles
on the palms of the hands and soles of
the feet in humans may suggest the
presence of another source of stem cells
for reepithelialization after severe
wounds or burns in this volar skin.
One candidate location is an eccrine
sweat gland, as eccrine glands are
abundant in the palm and sole.
Eccrine glands are composed of four
segments: the intraepidermal duct, the
straight intradermal duct, the coiled
intradermal duct (the most proximal
duct), and the secretory portion. In
contrast to the stem cells in hair
follicles, however, the localization of
stem cells in the eccrine gland has been
poorly characterized.
Before exploring the localization of
stem cells in the mouse eccrine glands,
we examined the development of
mouse eccrine glands by immunohis-
tochemistry with anti-keratin 14 anti-
body. Mice have eccrine sweat glands
only in their footpads. An immunohis-
tochemical study of cryosections from
the hind footpads of BALB/c Cr Slc mice
showed that, at embryo day 17.5, the
first sign of eccrine gland development
appeared as an epidermal downgrowth
in the mesenchymal condensation
of the hind footpads (data not shown).
The tips of eccrine gland rudiments
penetrated deep into the dermis after
birth, and began to produce epithelial
columns, which extended further dee-
ply into the dermis. One week after
birth, intraepidermal ducts were formed
and the whole sweat gland formation
was completed around day 14 after
birth.
To address the localization of stem
cells in the mouse eccrine glands, we
used a peculiar character of stem cells;
they are very slow cycling cells and
retain labels in the nucleus over several
weeks (Cotsarelis et al., 1990). We
performed BrdU pulse-chase experi-
ments in BALB/c Cr Slc mice as
described earlier (Nakamura and
Ishikawa, 2008). Five newborn BALB/c
Cr Slc mice were purchased from the
SLC Company (Hamamatsu, Japan)
and maintained in the Institute of
Laboratory Animals, Kyoto University.
Subcutaneously, 100mg/kg/day BrdU
(Sigma-Aldrich, St Louis, MO) was
injected daily for 5 days. Mice were
killed after 4 weeks and the frozen hind
footpad sections were stained with a
BrdU IHC Kit (Kamiya Biochemical
Company, Seattle, WA) according
to the manufacturer’s instructions.
Label-retaining cells were present
in the eccrine secretory gland and
coiled duct, but not in the straight duct
or intraepidermal duct (data not
shown).
To investigate the localization of
stem cells in the human eccrine glands,
we transplanted human skin onto the
back skin of BALB/c nude mice, after
obtaining approval from the Kyoto
University ethical committee and writ-
ten informed consent from the patients.
The study was conducted according to
the Declaration of Helsinki Principles.
Histologically normal skin was ob-
tained from five patients (ages from 37
to 72 years), three males and two
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